{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:56:59Z","timestamp":1793905019292,"version":"4.8.0"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Gout, an inflammatory arthritis caused by hyperuricemia, is highly prevalent with chronic kidney disease (CKD). We evaluated longitudinal changes in serum urate (SU) levels and febuxostat dosage according to renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 405 patients in the Urate-Lowering Therapy in Gout (ULTRA) registry between November 2021 and December 2023, 112 were analyzed after excluding those with &lt; 1-year follow-up period, nonfebuxostat therapy, or missing data. SU levels and febuxostat doses were compared between the 2 groups at baseline, 6, and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline SU levels did not differ between the normal and CKD groups. After febuxostat therapy, mean (SD) SU levels were significantly lower in the CKD group than in the normal group (at 6 months: 4.45 [1.84] mg\/dL vs 5.62 [1.62] mg\/dL,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001; at 12 months: 4.81 [1.81] mg\/dL vs 5.60 [1.94] mg\/dL,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). Meanwhile, the mean dosages of febuxostat were lower in CKD group than in the normal group (at 6 months: 40.61 [22.07] mg vs 47.54 [19.43] mg,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.11; at 12 months: 40.59 [21.73] mg vs 48.49 [19.70] mg,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.06), although these differences were not statistically significant. Additionally, the proportion of patients achieving SU &lt; 6 mg\/dL at 6 months was higher in the CKD group than in the normal group (91.2% vs 68.6%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An individualized dosing strategy based on SU response, rather than renal function alone, may optimize treatment outcomes in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0881","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:05:12Z","timestamp":1764597912000},"page":"322-328","source":"Crossref","is-referenced-by-count":2,"title":["Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-3481","authenticated-orcid":false,"given":"Yoon-Jeong","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-6151","authenticated-orcid":false,"given":"Hyo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-7939","authenticated-orcid":false,"given":"Sang-Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9523","authenticated-orcid":false,"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-4065","authenticated-orcid":false,"given":"In Ah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-1415","authenticated-orcid":false,"given":"Min Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-7598","authenticated-orcid":false,"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-1584","authenticated-orcid":false,"given":"Hyun-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1981-742X","authenticated-orcid":false,"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-4435","authenticated-orcid":false,"given":"Joong Kyong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-3806","authenticated-orcid":false,"given":"Chang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-7480","authenticated-orcid":false,"given":"Se Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-9624","authenticated-orcid":false,"given":"Kyeong Min","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-8328","authenticated-orcid":false,"given":"Ki Won","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-2190","authenticated-orcid":false,"given":"Chang-Nam","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026032910412634000_53.3.322.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"2026032910412634000_53.3.322.2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.rdc.2022.06.009","article-title":"Environmental triggers of hyperuricemia and gout","volume":"48","author":"Helget","year":"2022","journal-title":"Rheum Dis Clin N Am"},{"key":"2026032910412634000_53.3.322.3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/BOR.0000000000000691","article-title":"Comorbidities in gout and hyperuricemia: causality or epiphenomena?","volume":"32","author":"Sumpter","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2026032910412634000_53.3.322.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.033"},{"key":"2026032910412634000_53.3.322.5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40744-024-00681-2","article-title":"Projected health and economic burden of comorbid gout and chronic kidney disease in a virtual US population: a microsimulation study","volume":"11","author":"Card-Gowers","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026032910412634000_53.3.322.6","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000034910.58454.FD"},{"key":"2026032910412634000_53.3.322.7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/03007995.2015.1087979","article-title":"Why focus on uric acid?","volume":"31","author":"Johnson","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2026032910412634000_53.3.322.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.38171"},{"key":"2026032910412634000_53.3.322.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"2026032910412634000_53.3.322.10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3904\/kjim.2018.423","article-title":"Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"2026032910412634000_53.3.322.11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40744-022-00480-7","article-title":"Febuxostat therapy for patients with gout and Stage 2-4 CKD: a retrospective study","volume":"9","author":"Zhang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026032910412634000_53.3.322.12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jcpt.13794","article-title":"Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: a double-centre, randomized, controlled study","volume":"47","author":"Yang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026032910412634000_53.3.322.13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1756-185X.14666","article-title":"The aftermath of Urate-Lowering TheRApy in gout (ULTRA) registry: the first prospective observational multicenter cohort of Korean patients with gout","volume":"26","author":"Moon","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2026032910412634000_53.3.322.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"2026032910412634000_53.3.322.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046"},{"key":"2026032910412634000_53.3.322.16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026032910412634000_53.3.322.17","doi-asserted-by":"crossref","first-page":"1526182","DOI":"10.3389\/fneph.2025.1526182","article-title":"Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3\/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study","volume":"5","author":"Waheed","year":"2025","journal-title":"Front Nephrol"},{"key":"2026032910412634000_53.3.322.18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","article-title":"Uric acid and chronic kidney disease: still more to do","volume":"8","author":"Johnson","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026032910412634000_53.3.322.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00657-4"},{"key":"2026032910412634000_53.3.322.20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-363"},{"key":"2026032910412634000_53.3.322.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131240"},{"key":"2026032910412634000_53.3.322.22","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.107"},{"key":"2026032910412634000_53.3.322.23","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200501000-00005"},{"key":"2026032910412634000_53.3.322.24","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2147\/JIR.S458250","article-title":"Predictors of inadequate serum urate response to low-dose febuxostat in male patients with gout","volume":"17","author":"Sun","year":"2024","journal-title":"J Inflamm Res"},{"key":"2026032910412634000_53.3.322.25","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1093\/rheumatology\/keaf076","article-title":"Obesity reduces the urate-lowering efficacy among patients with primary gout: a prospective cohort study","volume":"64","author":"Cheng","year":"2025","journal-title":"Rheumatology"},{"key":"2026032910412634000_53.3.322.26","doi-asserted-by":"crossref","first-page":"e2430700","DOI":"10.1001\/jamanetworkopen.2024.30700","article-title":"Consumption of total and specific alcoholic beverages and long-term risk of gout among men and women","volume":"7","author":"Lyu","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:41:57Z","timestamp":1774806117000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.3899\/jrheum.2025-0881"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0881","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}